Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26981251 | 0.86 | ROCK2 (0.46) | ROCK2 | |
| SCHEMBL29470914 | 0.84 | ROCK2 (0.47) | ROCK2HSP90AA1HSP90AB1 | |
| SCHEMBL1013646 | 0.84 | ROCK2 (0.47) | ROCK2HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL28192456 | 0.84 | ROCK2 (0.35) | ROCK2 | |
| SCHEMBL26683536 | 0.84 | ROCK2 (0.37) | ROCK2 | |
| SCHEMBL28152688 | 0.81 | ROCK2 (0.38) | ROCK2 | |
| SCHEMBL21044754 | 0.81 | ROCK2 (0.43) | ROCK2 | |
| SCHEMBL28005452 | 0.80 | ROCK2 (0.39) | ROCK2 | |
| SCHEMBL5379529 | 0.79 | PTPN1 (0.35) | — | |
| SCHEMBL28213747 | 0.77 | ROCK2 (0.45) | ROCK2HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219521-A1 | NEW 2-(DIETHYLAMINO)-4,6-DIPHENYLBENZENE-1,3-CARBONITRILE DERIVATIVES, METHOD OF THEIR PRODUCTION, THEIR USE AND NEW PHOTOINITIATING SYSTEMS FOR PHOTOINITIATED CATIONIC, RADICAL, THIOL-ENE AND HYBRID POLYMERIZATION | Politechnika Krakowska im. Tadeusza Kościuszki (PL) | 2023-11-16 | — | — | WO | claimed |
| WO-2020120539-A1 | NEW PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-18 | — | — | WO | claimed |
| WO-2010020628-A1 | NOVEL PRODUCTION METHOD FOR L-PIPERIDINE-4-YL-1,3-DIHYDRO-IMIDAZO [4,5-B] PYRIDINE-2-ONE AND MONO- AND DIHYDROCHLORIDES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-25 | — | — | WO | claimed |
| US-20250136585-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER | LT MATERIALS CO., LTD. (KR) | 2025-05-01 | — | — | US | disclosed |
| WO-2024133551-A1 | PESTICIDALLY ACTIVE PYRIDAZINE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024123967-A1 | SARM1 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SENYA PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024110554-A1 | N-[(1 -[2-[6-(PYRIDAZIN-3-YL]-1,2,4-TRIAZOL-3-YL]ETHYL]-QUINAZOLIN-4-AMINE AND N-[1-[3-(6-(PYRIDAZIN-3-YL)PYRAZIN-2-YL]ETHYL]-8-QUINAZOLIN-4-AMINE DERIVATIVES AS PESTICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2024-05-30 | — | — | WO | disclosed |
| US-20240140951-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2024-05-02 | — | — | US | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-11919918-B2 | P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2024-03-05 | — | — | US | disclosed |
| EP-3712144-B1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2024-02-14 | — | — | EP | disclosed |
| US-20100197590-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | disclosed |
| WO-2010086820-A1 | 4-AMINO-5-OXO-7, 8-DIHYDROPYRIMIDO [5,4-F] [1,4] OXAZEPIN-6 (5H) -YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | PFIZER INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-7718645-B2 | Substituted bicyclolactam compounds | PFIZER INC. (US) | 2010-05-18 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | PFIZER INC | 2009-05-28 | — | — | US | disclosed |
| US-20090088451-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | ROCK2 4464/4885HSP90AA1 1650/4885HSP90AB1 1270/4885 |
| US-20100197590-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | CYP3A7, QDPR, DHFR | ROCK2 3386/4885HSP90AA1 4474/4885HSP90AB1 4428/4885 |
| US-20240140951-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | IL17A, IL15, IL2 | ROCK2 3893/4885HSP90AA1 1422/4885HSP90AB1 1083/4885 |
| US-11919918-B2 | P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | P2RX3, P2RX2, P2RX1 | ROCK2 4379/4885HSP90AA1 2450/4885HSP90AB1 2311/4885 |
| US-20090088451-A1 | QUINOLINES | HTR5A, HTR1A, HTR1E | ROCK2 2208/4885HSP90AA1 4015/4885HSP90AB1 4174/4885 |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CXCR2 | ROCK2 886/4885HSP90AA1 4539/4885HSP90AB1 4364/4885 |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CXCR2 | ROCK2 886/4885HSP90AA1 4539/4885HSP90AB1 4364/4885 |
| US-20250136585-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER | ORC3, CYP1B1, CRY1 | ROCK2 4332/4885HSP90AA1 4552/4885HSP90AB1 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.